Ann: Appendix 4C and Quarterly Update, page-19

The information flow is entering new territory. We are now getting names and details.

The canine compassionate usage has concluded to conserve the original supply of US Vet MPL tablets for Phase 3.
Dr, Agnew has been assigned to assist PAA with closing a commercial deal. Interesting that he is currently employed in R&D by Boehringer Ingelheim. Joining the dots, I infer that Boehringer must be very interested in our Doggie trials. Being one of the world's largest animal healthcare companies, they could snap up monepantel for veterinary use in an instant.

Looking forward to Covid, we now see that sites in Eastern Europe are under consideration for potential human trials in Q1 2022. This is contingent upon MPL performance at Leiden Organoid testing. The fact that human trials are being mentioned in the announcement indicates that the Board considers a good result in Organoid testing to be more than likely.

News from India that their production of MPL is on track is very important for our timelines.

Human MND trial due to commence Q4 after 3 month shelf life stability of our new tablets.
Human cancer trial sites are being considered in Italy and UK in Q1 2022 after PK data from MND trial.

This is all panning out rather well. Maybe missing out on a lowball Elanco offer could have been a blessing in disguise.

As a quick reminder, here is a list of Dr. Mollard's performance options:

Good luck to all...Thrifty